SRNE - Sorrento unit Scilex gets license to commercialize Romeg's gout treatment Gloperba

Scilex, a unit of Sorrento Therapeutics (NASDAQ:SRNE), on Tuesday said it had entered into a licensing and commercialization agreement with Romeg Therapeutics for the right to market and distribute in the U.S. Gloperba, an oral solution for gout. Romeg's Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Scilex will use its direct distribution network to national and regional wholesalers and pharmacies throughout all U.S. states to market and distribute Gloperba. SRNE's Scilex in March signed a merger agreement with special purpose acquisition company Vickers Vantage Corp. I (NASDAQ:VCKA) to go public at a pro forma equity valuation of ~$1.6B. SRNE stock +1.1% to $1.41 in morning trading.

For further details see:

Sorrento unit Scilex gets license to commercialize Romeg's gout treatment Gloperba